In our critique of a pay-to-participate study, we address how the failure to disclose study-related payments appears to have violated STEM CELLS Translational Medicine's editorial policies concerning conflict-of-interest and financial disclosure. Our analysis also identifies broader ethical issues and scientific concerns related to pay-to-participate studies conducted by businesses with a record of selling purported stem cell treatments before determining whether the products they sell are safe and efficacious. Authors of peer-reviewed articles have a responsibility to comply with journal policies and disclose financial conflicts of interest to editors, reviewers, and readers. Authors should also disclose when stem cell interventions being tested in clinical trials have already been sold on a direct-to-consumer basis as “stem cell treatments” by authors' affiliate institutions. Financial conflicts of interest and other forms of possible bias must be disclosed to put clinical studies in context and facilitate the critical assessment of research methods, findings, and conclusions. The apparent failure to comply with journal editorial policies and disclose such financial conflicts warrants careful investigation.

中文翻译：

---

有关付费参与干细胞研究的伦理问题

在我们对付费参与研究的批评中，我们讨论了未能披露与研究相关的付款似乎违反了STEM CELLS Translational Medicine有关利益冲突和财务披露的编辑政策。我们的分析还确定了与付费参与研究相关的更广泛的道德问题和科学问题，这些研究是由有销售所谓干细胞治疗记录的企业在确定其销售的产品是否安全有效之前进行的。同行评审文章的作者有责任遵守期刊政策并向编辑、审稿人和读者披露经济利益冲突。作者还应披露在临床试验中测试的干细胞干预措施何时已由作者的附属机构作为“干细胞治疗”直接向消费​​者出售。必须披露财务利益冲突和其他形式的可能偏见，以便将临床研究置于背景之下，并促进对研究方法、发现和结论的批判性评估。明显未能遵守期刊编辑政策并披露此类财务冲突，值得仔细调查。